肾上腺功能不全的未来方向:细胞移植与基因治疗
本文综述肾上腺皮质细胞移植与基因治疗的研究进展,旨在替代口服糖皮质激素治疗原发性肾上腺功能不全(PAI)。生理性皮质醇分泌有望通过同种异体肾上腺皮质细胞移植、干细胞或谱系转化生成类肾上腺类固醇生成细胞,或针对先天性肾上腺增生(CAH)的基因治疗实现。肾上腺皮质为高更新器官,移植中前体细胞整合不足将导致移植物耗竭,鉴定肾上腺皮质前体细胞对基因治疗同样重要。
要点
- 口服皮质醇替代虽可挽救生命,但生活质量差、反复肾上腺危象及缺乏验证性糖皮质激素充足生物标志物导致的剂量不确定性持续存在。
- 肾上腺皮质细胞移植与基因治疗可能规避激素替代的诸多缺点,但需解决前体细胞鉴定与移植物长期存活问题。
核心结论
- 细胞移植与基因治疗有望为儿童和成人原发性肾上腺功能不全实现生理性皮质醇分泌。
研究设计与样本
- 综述,检索范围未明确报告。
主要发现
- 成人主要病因为自身免疫性肾上腺炎,儿童主要病因为先天性肾上腺增生。
- 口服皮质醇替代可挽救生命,但生活质量差、反复肾上腺危象及剂量不确定性持续存在。
- 肾上腺皮质为高更新器官,移植中前体细胞整合不足将导致移植物耗竭。
- 鉴定肾上腺皮质前体细胞对基因治疗同样重要,需将新遗传物质特异性整合入前体细胞基因组以确保持久效果。
关键数值与推荐
- 生理性皮质醇分泌可由垂体促肾上腺皮质激素调控,通过同种异体肾上腺皮质细胞移植、干细胞或分化细胞谱系转化生成类肾上腺类固醇生成细胞,或针对先天性肾上腺增生的基因治疗替换或修复缺陷基因实现。
- 递送基因编辑工具与供体模板以实现21-羟化酶基因靶向校正,具有达成持久效果的潜力。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Primary adrenal insufficiency (PAI) occurs in 1 in 5 to 7000 adults. Leading etiologies are autoimmune adrenalitis in adults and congenital adrenal hyperplasia (CAH) in children. Oral replacement of cortisol is lifesaving, but poor quality of life, repeated adrenal crises, and dosing uncertainty related to lack of a validated biomarker for glucocorticoid sufficiency persists. Adrenocortical cell therapy and gene therapy may obviate many of the shortcomings of adrenal hormone replacement. Physiological cortisol secretion regulated by pituitary adrenocorticotropin could be achieved through allogeneic adrenocortical cell transplantation, production of adrenal-like steroidogenic cells from either stem cells or lineage conversion of differentiated cells, or for CAH, gene therapy to replace or repair a defective gene. The adrenal cortex is a high-turnover organ and thus failure to incorporate progenitor cells within a transplant will ultimately result in graft exhaustion. Identification of adrenocortical progenitor cells is equally important in gene therapy, for which new genetic material must be specifically integrated into the genome of progenitors to ensure a durable effect. Delivery of gene-editing machinery and a donor template, allowing targeted correction of the 21-hydroxylase gene, has the potential to achieve this. This review describes advances in adrenal cell transplants and gene therapy that may allow physiological cortisol production for children and adults with PAI.
引用
- Graves LE, Torpy DJ, Coates PT, et al. Future Directions for Adrenal Insufficiency: Cellular Transplantation and Genetic Therapies. J Clin Endocrinol Metab. 2023. PMID: 36611246. doi:10.1210/clinem/dgac751
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。